Dr. T. Peter Kingham

Dr. T. Peter Kingham is Associate Professor of Surgery at Weill Cornell Medicine and Attending Surgeon on the Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center, where he synchronizes surgeons, medical and radiation oncologists, interventional radiologists, hepatologists, pathologists, genetic counselors, dietitians, pharmacists, and social workers into one daily conference so each person walks into clinic with a single, well-coordinated plan rather than a chain of separate appointments. Same-day cytology, rapid-sequence MRI, and anesthesia reviews compress the interval from suspicion to definitive therapy, while bilingual nurse navigators arrange scans, tele-visits, and insurance clearances in one call, sparing families repeated travel. A secure portal lists procedure dates, laboratory trends, and direct-message links that deliver answers within hours, building trust through transparent communication. Patients therefore move through a carefully choreographed pathway that begins with unified expertise and ends with long-term survivorship support, confident that every decision reflects consensus among specialists who share information continuously.

 

Much of Dr. Kingham’s translational research centers on regional liver-directed therapy, particularly hepatic-artery-infusion pump (HAIP) chemotherapy for colorectal liver metastases and cholangiocarcinoma. His flagship protocols combine pump-delivered floxuridine with perfusion mapping and circulating-tumor-DNA surveillance, refining dose intensity while safeguarding healthy parenchyma; parallel bench studies culture patient-derived organoids exposed to arterial drug gradients, revealing gene-expression shifts that guide adjuvant sequencing. Publications comparing robotic, laparoscopic, and open HAIP placement demonstrate lower conversion rates and shorter hospital stays when minimally invasive techniques are used, findings now adopted across multiple centers. Data from every case feed a living biobank that aligns genomic, transcriptomic, and spatial-proteomic profiles with outcome, letting data-science teams build algorithms that flag resistance patterns before scans reveal progression. By looping laboratory insight directly back to bedside practice, he offers participants therapies that evolve alongside tumor biology while accelerating progress for future patients.

 

Dr. Kingham also directs Memorial Sloan Kettering’s Global Cancer Disparities Initiatives, co-founding the African Research Group for Oncology consortium that unites twenty-five Nigerian hospitals in colorectal-cancer research, training, and guideline development. Workshops streamed from New York demonstrate pump placement and parenchymal-sparing hepatectomy; visiting-scholar programs bring Nigerian surgeons and pathologists to MSK for immersive fellowships, while mobile endoscopy units extend screening to rural districts. Collaborative toolkits—produced with Surgeons Overseas, the nonprofit he helped launch—explain early warning signs, treatment financing, and postoperative nutrition in English and Yoruba, empowering patients to seek timely care. Ongoing NIH-funded studies examine immune-checkpoint biology in West-African tumors, ensuring discoveries account for genetic diversity. By blending capacity building, mentorship, and bidirectional research, he strengthens cancer care where resources are scarce and offers families everywhere the assurance that their surgeon fights disparities as rigorously as disease.